State of Alaska Department of Revenue Has $965,000 Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

State of Alaska Department of Revenue lessened its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 64.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,906 shares of the company's stock after selling 5,245 shares during the period. State of Alaska Department of Revenue's holdings in Medpace were worth $965,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of MEDP. Iron Triangle Partners LP bought a new position in Medpace in the 3rd quarter valued at about $64,371,000. Wellington Management Group LLP grew its position in Medpace by 36.0% in the 3rd quarter. Wellington Management Group LLP now owns 415,255 shares of the company's stock valued at $138,612,000 after buying an additional 109,886 shares in the last quarter. DF Dent & Co. Inc. grew its position in Medpace by 189.9% in the 3rd quarter. DF Dent & Co. Inc. now owns 161,298 shares of the company's stock valued at $53,841,000 after buying an additional 105,659 shares in the last quarter. Argent Capital Management LLC boosted its position in shares of Medpace by 431.5% during the 3rd quarter. Argent Capital Management LLC now owns 91,732 shares of the company's stock valued at $30,620,000 after purchasing an additional 74,473 shares in the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec bought a new position in shares of Medpace during the 3rd quarter valued at about $23,321,000. Institutional investors own 77.98% of the company's stock.

Medpace Trading Down 0.7 %

MEDP stock traded down $2.24 during mid-day trading on Monday, reaching $340.17. 299,085 shares of the stock traded hands, compared to its average volume of 208,882. Medpace Holdings, Inc. has a 52-week low of $302.01 and a 52-week high of $459.77. The company has a market cap of $10.57 billion, a P/E ratio of 29.79, a P/E/G ratio of 1.85 and a beta of 1.36. The stock's fifty day moving average is $343.50 and its 200-day moving average is $348.07.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.96 by $0.71. Medpace had a net margin of 17.66% and a return on equity of 50.87%. Equities research analysts expect that Medpace Holdings, Inc. will post 11.93 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. William Blair restated an "outperform" rating on shares of Medpace in a research report on Tuesday, October 22nd. Baird R W lowered shares of Medpace from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, October 23rd. Robert W. Baird raised their price objective on shares of Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a research report on Monday, January 27th. Finally, TD Cowen reduced their price objective on shares of Medpace from $413.00 to $372.00 and set a "buy" rating for the company in a research report on Wednesday, October 23rd. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $381.44.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.